BioCryst Pharmaceuticals,Inc. (BCRX)

[agribusiness72]

great dd

https://www.reddit.com/r/BCRX/comments/lapxd4/question_3_what_is_biocrysts_galidesivir_drug/?utm_source=share&utm_medium=ios_app&utm_name=iossmf

[agribusiness72]

Why buy bcrx?

https://docs.google.com/document/u/0/d/1Kb9dRs56cnsciFm-OiD5MzKnaYcsqQWB_SFDkQJScH8/mobilebasic

[agribusiness72]

Going to be a great year. Especially with the Factor D!

[Deano361]

Well with Redditt it might happen like we thought the Galide would do. WE shall see

[agribusiness72]

My sell point is 200. I may be gone by end of year, lol

[ClayTrader]

* * $BCRX Video Chart 02-01-2021 * *

Link to Video - click here to watch the technical chart video

[Deano361]

They are finally right about that. They were also right about massive short positions in the others they played. We will get more upside from this.

[agribusiness72]

https://seekingalpha.com/amp/news/3656590-biocryst-climbs-after-being-named-the-most-undervalued-stock-in-the-market?source=feed_f&utm_campaign=twitter_automated&utm_content=news&utm_medium=social&utm_source=twitter_automated&__twitter_impression=true

[Femto99]

https://msmoneymoves.com/2021/01/31/this-is-big/amp/?__twitter_impression=true

[AlphaStockNews]

$BCRX is screaming for the top this morning after BlackRock disclosed ownership. There's more to the story. https://cnafinance.com/bcrx-stock-biocryst-heads-up-on-blackrock-ownership/

[Limey42]

Those Webull peeps are loving the pre-market price action lol......can it be sustained when market opens?

[dawsons creek]

This is exactly it, way undervalued, great pipeline of drugs, so much more to the story, this is just getting more eyes on it!!

[agribusiness72]

Buyers need to hold strong. This is just the beginning. unlike the others bcrx is a huge revenue generating and people first business. Research shows exactly how undervalued this is. Proper valuation is 59 per share based on US and Japan approvals only. Add the EU and factor D. 200+ by 2023. No other stock has this potential based on facts!

[dawsons creek]

#biowar Monday ongoing

[dawsons creek]

Totally agree, pipeline is so strong, but the movement could help kick starter faster. Should be some fireworks! I hope we hit your mark, brews all around!

[agribusiness72]

Exactly right. Regardless of what this consolidated effort brings, this will be a triple digit stock in the near future. Facts are a plenty. Know what you own. Upped my limit sell order of 8000 shares to $200. That's 1.6 million dollars. The remaining 885 I'll hold and watch with delight!

[dawsons creek]

Be prepared tomorrow #biowar Monday is coming tomorrow! Stocktwits, Reddit and wallstreetbets are doing their thing! ????????????????????????

[Limey42]

Not sure this will amount to much if the overall market is red on Monday. Lot of the big players are liquidating assets across the board right now, so I'm not holding out much hope. Fundamentals are awesome though, so it will grow organically at some point, of that I have no doubt.

[Dartgator]

I am overweight with BCRX right now, adding more shares is my new addiction!

[agribusiness72]

orchestrated squeeze for monday is being attempted. not sure how it will go but thousands are now being told the biocryst story. Monday will be interesting for sure.

[agribusiness72]

Same here!

[Limey42]

It's a no brainer in my mind. Once earnings start getting reported then everything will align. I'll keep adding bit by bit for now. GL.

[agribusiness72]

Nice increase by Blackrock. Professionals know where this is going.

[Limey42]

Nice increase by Denner!

[Femto99]

Statement of Ownership (sc 13g) Tute loading up!

[Crack_Me_Up]

Zacks PR today: BioCryst (BCRX) Wins Japanese Approval for HAE Drug Orladeyo

https://finance.yahoo.com/news/biocryst-bcrx-wins-japanese-approval-142802309.html

BioCryst Pharmaceuticals, Inc. BCRX announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval to oral, once-daily Orladeyo (berotralstat) 150 mg for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years or older.

Shares of BioCryst have surged 186.9% in the past year compared with the industry’s growth of 0.5%.

Orladeyo is the first and only prophylactic HAE medication approved in Japan. One capsule of Orladeyo per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein.The approval in Japan was based on data from APeX-J and APeX-2 studies. The APeX-J study in Japan met its primary endpoint of a reduction in HAE attacks from baseline for Orladeyo 150 mg compared to placebo, and Orladeyo was safe and generally well-tolerated in the study.

Orladeyo significantly reduced attacks at 24 weeks and this reduction was sustained through 48 weeks as observed in the phase III APeX-2 study. HAE patients who completed 48 weeks of treatment (150 mg) saw reductions in their HAE attack rates, from a mean of 2.9 attacks per month at baseline to a mean of 1.0 attacks, following 48 weeks of therapy.

Orladeyo is a plasma kallikrein inhibitor.

Orladeyo will be commercialized in Japan by BioCryst’s partner, Torii Pharmaceutical Co., Ltd. OrphanPacific, Inc. is BioCryst’s representative partner in Japan and holds the marketing authorization.

With the approval in Japan, BioCryst is eligible to receive an additional milestone payment of $15 million from Torii. Further, BioCryst will receive tiered royalties ranging from 20% to potentially 40% of Japanese net sales.

In December 2020, the FDA approved Orladeyo in the United States. In Europe, the European Medicines Agency (EMA) validated its marketing authorization application (MAA) submission for Orladeyo and a review of the MAA is ongoing. The company expects an approval decision in Europe in the second quarter of 2021.

Meanwhile, the company has a deep pipeline with several ongoing development programs that include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; galidesivir, a potential treatment for COVID-19, Marburg virus disease and Yellow Fever; and BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva.

[Crack_Me_Up]

From 71.2% to 73.95% % of Shares Held by Institutions, a positive sign.

https://finance.yahoo.com/quote/BCRX/holders?p=BCRX

[Crack_Me_Up]

Merck opening the door to BCRX? Merck ends COVID vaccine program, cites inferior immune responses

https://www.yahoo.com/news/merck-ends-covid-vaccine-program-115825711.html

Drugmaker Merck & Co said on Monday it would stop development of its two COVID-19 vaccines and focus pandemic research on treatments, with initial data on an experimental oral antiviral expected by the end of March.

Merck was late to join the race to develop a vaccine to protect against the coronavirus, which has so far killed more than 2 million people and continues to surge in many parts of the world including the United States.

The company will record a pre-tax discontinuation charge in the fourth quarter for vaccine candidate V591, which it acquired with the purchase of Austrian vaccine maker Themis Bioscience, and V590, developed with nonprofit research organization IAVI, Merck said in a statement.



In early trials, both vaccines generated immune responses that were inferior to those seen in people who had recovered from COVID-19 as well as those reported for other COVID-19 vaccines, the company said.

The announcement is a setback to the fight against the pandemic and comes a month after Sanofi and GlaxoSmithKline delayed launch of their shot to late 2021, underscoring the challenges of developing vaccines at record speed.

Tens of millions of doses of vaccines from rivals Pfizer Inc and German partner BioNTech as well as from Moderna Inc have so far been administered globally.

Johnson & Johnson, AstraZeneca Plc and others are also racing to develop safe and effective vaccines to protect against the virus.

Merck said it would focus COVID-19 research and manufacturing efforts on two investigational medicines: MK-7110 and MK-4482, which it now calls molnupiravir.

Molnupiravir, which is being developed in collaboration with Ridgeback Bio, is an oral antiviral being studied in both hospital and outpatient settings.

Merck said a Phase 2/3 trial of the drug was set to finish in May, but initial efficacy results were due in the first quarter and would be made public if clinically meaningful.

Merck said results from a Phase 3 study of MK-7110, an immune modulator being studied as a treatment for patients hospitalized with severe COVID-19, were expected in the first quarter.

Shares of Merck fell 1% to $80.12 in trading before the bell.

(Reporting By Deena Beasley and additional reporting by Manas Mishra in Bengaluru; Editing by Shri Navaratnam and Anil D'Silva)

[wolverine_investor]

Hey Deano,

glad to hear you are still around, hope you are doing well!

I see a lot of you longs are still in this, me too

Today is the first time in a while that we are getting manipulation on good news.... we've been through this before, we are hardened. We'll hit 15 this year... we all know it. (and that could be a conservative estimate)

[AlphaStockNews]

$BCRX is headed for the top in the market this morning after announcing Japanese approval of ORLADEYO. https://cnafinance.com/bcrx-stock-biocryst-climbs-on-approval/

[Deano361]

Hey , you bet ! Took a new day job . Hope don’t need it soon lol! Yes revenue and factor d now the key for 2021z going to be nice and steady up

[agribusiness72]

Are you still in this? Going to be a fantastic year. Japan just approved Orladeyo, UK next. Continuing to rise. Last conference was very exciting with Factor D moving forward. No doubt over a hundred in 2023. Over 10 today!

[agribusiness72]

Exactly, 8k is filed. 10K will have updates, 10Q will have revenues, 2nd 10Q will include Japans revenues, 3rd 10Q will have UK revenues, and all for Orladeyo. The factor D and galidesivir going to make this a hundred dollar stock by 2022/23. Exciting times ahead.

[Limey42]

Japan approval...nice. Revenues up next.

[agribusiness72]

The big pharma companies steer away from rare diseases. not enough money in it. That's where these smaller companies come in. Wouldn't be til 2023 when factor D is fully vetted that a large company would be interested. By then we could be at 200 per share or above,

[Crack_Me_Up]

Only 6 working days for an announcement. EOM

[Crack_Me_Up]

Agree but big pharma is not going to sit on their hands and let BCRX take any market shares from them especially in today's world where rare disease treatments.

[agribusiness72]

you don't. ceo himself said they do what the big guys can't. This stock will be over 100 due to factor D , Orladeyo, and even galidesivir. getting bought out may give shareholders a premium on todays prices but nowhere near what we will soon see on its own.

[Crack_Me_Up]

How do you say major partnerships or buyout EOM

[agribusiness72]

yes indeed. once I hit a million in bcrx it will be hard not to sell. with a military retirement, 401k, Ira, social security, will be no need to get more. 120 by 2023 at the very latest.

[ANS414]

I’m jealous. I’m fully tapped out and may be locked in at 6,001 shares forever. While $120 doesn’t get me to retirement, $250 does. And I think there’s a real possibility that comes within 12 months of $120. We shall see.

[agribusiness72]

With Japans approval 10 to 11 pps. Uk Approval 15. Factor D - over 100!

[agribusiness72]

Bought another 540 shares at 9.00 now have almost 9000 shares. When at 120 per share it will be time to fully retire.

[ANS414]

Well, this is a fun morning.

[agribusiness72]

Every quarter. May have an update with 10K, but not financial numbers as insurance payments probably won't hit the books until Jan. 1st major update expected with 1st qtr report. Expect Japan approval next week with spike to $10.00 per. UK approval by end of March, though the UK has approved Orladeyo for use prior to official approval. See my previous post for link.

More interesting though will be their updates on their Factor D. My sell point is $120.00. Expected in 2023.

[ttubular]

When do we get the first one

[agribusiness72]

Hopefully a higher close as investors buy in before the long weekend. With Japans approval any day now and U.S. markets closed on Monday investors just might want to get ahead of the expected spike over 9/10 dollar range. If approval comes Monday shorts will be screwed. Last hour of trading will be very interesting.

[agribusiness72]

Small company like this is much better suited in the critical area of rare diseases. Key word rare. I believe that was discussed at the jpm conference. Biocryst will soar on its own. Will be much better for shareholders if they remain as is and make us all millionaires.

[Crack_Me_Up]

I agree, I still see a major partnership announcement or buy out. No way they will continue to allow this company to grow and start controlling sectors of the industry without influence from big pharma.

[Femto99]

"BCX9930 will make C-5 inhibitors obsolete" Bill Sheridan. That is north of $ 50b per year!